A threat group researchers call "Armored Likho" has gained access to government agencies and electrical power entities in ...

Armored Likho BusySnake Stealer, a Python-based infostealer first disclosed by Kaspersky, is actively targeting government ...

Fake CVE exploit repos pull frint and skytext packages to steal researcher credentials, with servers still live as of July 1.

On June 24, 2026, Microsoft’s Digital Crimes Unit (DCU) facilitated the takedown, suspension, and blocking of domains that ...

OpenAI is rolling out the full, limited-release version of GPT-5.5-Cyber—a specialized AI model that outperforms its predecessors and Claude Mythos 5 in security benchmarks like CyberGym.

Apple today announced that the Passwords app can now automatically update weak and compromised passwords using Apple Intelligence and Safari to take action on a user's behalf. The feature builds on ...

Apps from Apple, Google and others can assist in making your online accounts more secure, even as new ways of logging in continue to take off. By J. D. Biersdorfer J.D. Biersdorfer writes about how to ...

We independently review everything we recommend. When you buy through our links, we may earn a commission. Learn more› By Max Eddy Max Eddy is a writer who has covered privacy and security — including ...

We wouldn't blame you for assuming that AI, being a computer, would be better at generating passwords than a human. After all, people use AI to do everything from writing their emails to generating a ...

Generate:Biomedicines is the latest biotech to benefit from a renewed appetite from investors for publicly listed drug developers. Generate—which will list its stock on the Nasdaq this morning under ...

The era of AI has not been particularly great for cybersecurity. We know that vibe-coded websites and apps have been a hotbed of security flaws that leave the platforms vulnerable to attacks. It turns ...

Clinical-stage antibody company Generate:Biomedicines is the latest biotech to mull going public as momentum for IPOs continues to build. The Flagship-founded biotech has yet to set out how many ...